Alpha 2.0
Login Register
» Authors » Peter C Albertsen

Peter C Albertsen

Explore the profile of Peter C Albertsen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 179
Citations 4285
Followers 0
Related Specialties
Urology
Oncology
General Medicine
Top 10 Co-Authors
David F Penson
Janet L Stanford
Richard M Hoffman
Ann S Hamilton
Antoinette M Stroup
Michael Goodman
Michael J Barry
Grace L Lu-Yao
Tatsuki Koyama
H Ballentine Carter
Published In
J Urol
Eur Urol
BJU Int
J Natl Cancer Inst
JAMA
Affiliations
Soon will be listed here.
Recent Articles
1.
Michael Droller: Teacher, mentor, confidant and friend
Albertsen P
Urol Oncol . 2025 Feb; 43(2):113. PMID: 39986807
No abstract available.
2.
Screening for homologous recombination genes
Albertsen P
Prostate Cancer Prostatic Dis . 2024 Dec; PMID: 39643659
No abstract available.
3.
Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the...
Bjerner J, Bratt O, Aas K, Albertsen P, Carlsson S, Oldenburg J
Eur Urol . 2024 Sep; 86(6):e150-e151. PMID: 39294047
No abstract available.
4.
Cost-effective Prostate-specific Antigen Screening: Who Do We Screen and What Treatments Do We Offer?
Albertsen P
Eur Urol . 2024 Jun; 86(5):409-410. PMID: 38871520
No abstract available.
5.
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial
Martin R, Turner E, Young G, Metcalfe C, Walsh E, Athene Lane J, et al.
JAMA . 2024 Apr; 331(17):1460-1470. PMID: 38581198
Importance: The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary...
6.
Response to 'Endpoint and control group in prostate cancer screening research: public health basics'
Albertsen P
BJU Int . 2024 Mar; 134(2):315. PMID: 38553937
No abstract available.
7.
Screening and active surveillance in prostate cancer: the dilemma continues
Hamdy F, Albertsen P, Donovan J
BJU Int . 2024 Mar; 134(1):1-2. PMID: 38514989
No abstract available.
8.
Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge
Albertsen P, Bjerner L, Pasovic L, Muller S, Fossa S, Carlsson S, et al.
BJU Int . 2023 Oct; 133(1):104-111. PMID: 37869764
Objective: To describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide opportunistic PSA testing. Patients And Methods: Over 8 million PSA tests were performed...
9.
Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer
ONeil B, Hoffman K, Koyama T, Alvarez J, Conwill R, Albertsen P, et al.
Urol Pract . 2023 Jun; 5(6):471-479. PMID: 37312333
Introduction: Little is known about differences in patient reported outcomes between contemporary external beam radiation therapy for localized prostate cancer that delivers higher doses of conformal radiation and older techniques....
10.
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium
Bjerner J, Bratt O, Aas K, Albertsen P, Fossa S, Kvale R, et al.
Eur Urol . 2023 May; 86(1):20-26. PMID: 37169639
Background And Objective: Prostate-specific antigen (PSA) levels in midlife are strongly associated with the long-term risk of lethal prostate cancer in cohorts not subject to screening. This is the first...